News > Maharashtra plans to procure remdesivir

Maharashtra plans to procure remdesivir

Maharashtra is planning to procure 10,000 vials of Remdesivir, an anti-viral drug that is being tried globally on patients with severe COVID-19. The U.S.-based Gilead Sciences that has made the drug has signed non-exclusive voluntary licensing agreements with five generic pharmaceutical manufacturers - Cipla Ltd., Ferozsons Laboratories, Hetero Labs Ltd., Jubilant Lifesciences and Mylan - based in India and Pakistan to expand supply of the drug. The company hopes to make it available in July.